Pan-tumor MRD Study

Recruiting

• Conditions: Muscle Invasive Bladder Urothelial Carcinoma; Esophageal Cancer; Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma; Melanoma (Skin Cancer); NSCLC (Non-small Cell Lung Cancer); Pancreatic (Exocrine Only); Mix of Solid Tumors (MOST)

• Registration Number: NCT06605404
• Lead Sponsor: Flatiron Health

Brief Summary

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back.

Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-09
• Study First Submitted: 2024-09-18
• Study First Submitted QC: 2024-09-18
• Study First Posted: 2024-09-20
• Study Start: 2025-01
• Last Update Submitted: 2025-01-14
• Last Update Posted: 2025-01-15
• Primary Completion: 2031-12
• Study Completion: 2032-04

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1350

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood and tissue biospecimen registry	Observation from enrollment to 5.5 years after enrollment	To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.

Trial Locations

Locations (1)

Taylor Cancer Research Center; 🇺🇸 Maumee, Ohio, United States